We are live on ! Find out more
LAB icon

Standard BioTools
LAB

65 hedge funds and large institutions have $42.5M invested in Standard BioTools in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 28 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.68% less ownership

Funds ownership: 56.8% → 49.12% (-7.7%)

24% less funds holding

Funds holding: 86 → 65 (-21)

39% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 28

39% less capital invested

Capital invested by funds: $70.2M → $42.5M (-$27.7M)

54% less call options, than puts

Call options by funds: $44K | Put options by funds: $96K

84% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 25

Holders
65
Holders Change
-21
Holders Change %
-24.42%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
17
Reduced
28
Closed
25
Calls
$44K
Puts
$96K
Net Calls
-$52K
Net Calls Change
+$191K

Top Buyers

1
JCP
Jennifer C. Price
+$921K
2
Neuberger Berman Group
Neuberger Berman Group
New York
+$600K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$600K
4
BCM
Bridgeway Capital Management
Texas
+$245K
5
XT
XTX Topco
Cayman Islands
+$210K

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$3.18M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$1.82M
3
PVI
Pura Vida Investments
New York
-$902K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$860K
5
Millennium Management
Millennium Management
New York
-$657K
Name Holding Trade Value Shares
Change 		Change in
Stake
ICM
1
Indaba Capital Management
California
$8.19M – – –
Primecap Management
2
Primecap Management
California
$5.42M -$43.2K -28,600 -0.6%
Neuberger Berman Group
3
Neuberger Berman Group
New York
$4.81M +$600K +396,926 +10%
Vanguard Group
4
Vanguard Group
Pennsylvania
$4.35M +$600K +396,800 +11%
NIM
5
Needham Investment Management
New York
$4.25M -$17.8K -11,746 -0.3%
Morgan Stanley
6
Morgan Stanley
New York
$3.17M -$327K -216,292 -7%
BFM
7
Boothbay Fund Management
New York
$2.53M -$28.5K -18,844 -0.8%
BlackRock
8
BlackRock
New York
$2.18M -$48K -31,746 -2%
Millennium Management
9
Millennium Management
New York
$1.01M -$657K -434,263 -32%
JCP
10
Jennifer C. Price
$940K +$921K +609,200 +249%
D.E. Shaw & Co
11
D.E. Shaw & Co
New York
$888K -$124K -81,886 -9%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$778K +$1.87K +1,237 +0.2%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$429K -$860K -568,519 -59%
Renaissance Technologies
14
Renaissance Technologies
New York
$379K +$170K +112,200 +48%
State Street
15
State Street
Massachusetts
$310K -$80.3K -53,100 -16%
PVI
16
Pura Vida Investments
New York
$278K -$902K -596,868 -70%
HighTower Advisors
17
HighTower Advisors
Illinois
$272K -$134K -88,824 -26%
E
18
Ergoteles
New York
$217K -$229K -151,503 -43%
Tudor Investment Corp
19
Tudor Investment Corp
Connecticut
$212K – – –
Northern Trust
20
Northern Trust
Illinois
$188K +$2.81K +1,857 +1%
XT
21
XTX Topco
Cayman Islands
$178K +$210K +139,104 +611%
BCM
22
Bridgeway Capital Management
Texas
$178K +$245K +162,000 New
Rockefeller Capital Management
23
Rockefeller Capital Management
New York
$166K +$49.9K +33,000 +28%
CSS
24
Cubist Systematic Strategies
Connecticut
$126K -$16.7K -11,038 -9%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$113K +$79.2K +52,417 +104%
1
2 3 4

LAB Hedge Fund Activity: Q3 2022 in Review

65 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2022, worth a combined $42.5M — down 39% from $70.2M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of LAB and 4 opened new positions — a net loss of 21 holders — while 28 trimmed existing stakes and 17 added.

The largest buyer was Jennifer C. Price, adding an estimated $921K. The largest seller was RA Capital Management, exiting entirely with an estimated $3.18M sold.

  • 65 institutional investors held Standard BioTools (LAB) as of Q3 2022, down from 86 in Q2 2022.
  • Funds reported $42.5M of Standard BioTools stock for Q3 2022, down 39% quarter-over-quarter.
  • 4 funds opened new Standard BioTools positions in Q3 2022 and 25 closed out, a net change of -21 holders.
  • The largest Standard BioTools buyer in Q3 2022 was Jennifer C. Price, an estimated $921K added.
  • The largest Standard BioTools seller in Q3 2022 was RA Capital Management, an estimated $3.18M sold.

Based on aggregated 13F filings for Q3 2022.